Physician profile
Priya Swamy
NPI 1245285741
$1,995.22
in general payments reported to CMS, 2019-2025
20 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $52.30 · 2021: $69.27 · 2022: $231 · 2023: $543 · 2024: $490 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Travel and Lodging: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.94 |
| Travel and Lodging | $289.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $761.50 | 2019-2025 | Xtampza, Belbuca |
| Curonix LLC | $455.08 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biodelivery Sciences International, INC. | $113.93 | 2019-2021 | |
| Nevro Corp. | $102.25 | 2019-2023 | Senza |
| Protega Pharmaceutials INC | $89.24 | 2023 | Roxybond |
| Abbott Laboratories | $88.73 | 2019-2024 | Octrode |
| Spr Therapeutics, INC | $66.00 | 2023 | Sprint Pns System |
| Daiichi Sankyo INC. | $47.14 | 2019 | |
| Prescient Lab Services, LLC | $44.60 | 2025 | Avertd Biofilmchip Microarray Magazine, Avertd Intellipac Reagent Module, Avertd Amplification Mix |
| Pfizer INC. | $44.54 | 2019 | |
| Scilex Pharmaceuticals INC. | $39.91 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $29.51 | 2022-2023 | Seglentis |
| Boston Scientific Corporation | $23.61 | 2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $16.49 | 2019 | |
| Alfasigma USA, INC. | $14.84 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.07 | 2019 | |
| Virtus Pharmaceuticals LLC | $11.34 | 2021 | |
| Abbvie INC. | $11.12 | 2021 | |
| Forte Bio-Pharma LLC | $9.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Swamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.